Pre-made Narnatumab benchmark antibody ( Whole mAb, anti-MST1R/RON therapeutic antibody, Anti-RON/SEA/PTK8/CD136/NPCA3/CDw136 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Narnatumab biosimilar, Whole mAb, Anti-MST1R/RON Antibody: Anti-RON/SEA/PTK8/CD136/NPCA3/CDw136 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-365-1mg	1mg	3090
GMP-Bios-ab-365-10mg	10mg	Inquiry
GMP-Bios-ab-365-100mg	100mg	Inquiry
GMP-Bios-ab-365-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Narnatumab biosimilar, Whole mAb, Anti-MST1R/RON Antibody: Anti-RON/SEA/PTK8/CD136/NPCA3/CDw136 therapeutic antibody
INN Name	Narnatumab
Target	RON
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	ImClone Systems;Eli Lilly;ImClone Systems
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na